FDA Approves Xeljanz for Use in Psoriatic Arthritis Pfizer Inc. announced today that the United States Food and Drug Administration (FDA)… rheumnow.com Pfizer’s Xeljanz gets FDA nod as joint disease treatment U.S. drugmaker Pfizer Inc said on Thursday the U.S. Food and Drug… reuters.com OPAL Broaden: Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis nejm.org OPAL Beyond: Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors nejm.org